Apogenix GmbH   Report issue

For profit Phase 1 Phase 3
Founded: Heidelberg Germany (2005)

Organization Overview

First Clinical Trial
2009
NCT01071837
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Apogenix AG | Apogenix GmbH

Active Ingredients

Drugs in Phase 3 Trials (1)

apg101 (4 trials)

Drugs in Phase 1 Trials (1)

allogeneic bone marrow (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Pneumonia (Phase 2)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2